# Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

> **NCT04887298** · PHASE1,PHASE2 · COMPLETED · sponsor: **Moleculin Biotech, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Sarcoma,Soft Tissue
- Pulmonary Metastasis

## Interventions

- **DRUG:** Liposomal Annamycin (L-Annamycin)

## Key facts

- **NCT ID:** NCT04887298
- **Lead sponsor:** Moleculin Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-05
- **Primary completion:** 2022-09-29
- **Final completion:** 2024-08-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04887298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04887298, "Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04887298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*